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Andrea A Baccarelli1 and Hyang-Min Byun1,2*Abstract
Background: Platelets are critical in the etiology of cardiovascular disease (CVD), and the mitochondria in these
cells serve as an energy source for platelet function. Epigenetic factors, especially DNA methylation, have been
employed as markers of CVD. Unlike nuclear DNA methylation, mitochondrial DNA (mtDNA) methylation has not
been widely studied, in part, due to debate about its existence and role. In this study, we examined platelet mtDNA
methylation in relation to CVD.
Results: We measured mtDNA methylation in platelets by bisulfite-PCR pyrosequencing and examined associations
of CVD with methylation in mitochondrial genes; cytochrome c oxidase (MT-CO1, MT-CO2, and MT-CO3); tRNA
leucine 1 (MT-TL1); ATP synthase (MT-ATP6 and MT-ATP8); and NADH dehydrogenase (MT-MD5). We report that CVD
patients have significantly higher mtDNA methylation than healthy controls in MT-CO1 (18.53%, P < 0.0001), MT-CO2
(3.33%, P = 0.0001), MT-CO3 (0.92%, P < 0.0001), and MT-TL1 (1.67%, P = 0.0001), which are involved in ATP synthesis.
Platelet mtDNA methylation was not related with age, BMI, and race in this study.
Conclusions: Our results suggest that platelet mtDNA methylation, which could serve as non-invasive and
easy-to-obtain markers, may be implicated in the etiology of CVD.
Keywords: Mitochondrial epigenetics, DNA methylation, Platelet, Cardiovascular diseaseBackground
Cardiovascular disease (CVD) is the leading cause of
death in the United States, accounting for more than
800,000 deaths every year, corresponding to one of every
three deaths, or one every 40 s [1]. As the proportion of
Americans aged over 75 years is expected to increase
from 6% in 2000 to 11% in 2050, the health-care burden
due to CVD is similarly predicted to rise dramatically in
the coming years [2].
Platelets play an important role in CVD, both in the
pathogenesis of atherosclerosis and in the development
of acute thrombotic events. Abnormal platelets, either
quantitatively or qualitatively, are associated with CVD
[3-6]. Platelets process a rapid and complex signaling
cascade that regulates adhesion, aggregation, and activa-
tion to mediate thrombus formation. Platelets have a* Correspondence: Hyang-Min.Byun@newcastle.ac.uk
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unless otherwise stated.greater rate of ATP turnover than resting mammalian
muscle that contains high levels of mitochondria [7],
suggesting an essential role for mitochondria in platelet
function, and energy demand escalates during platelet
activation and secretion [8,9]. Mitochondrial DNA
(mtDNA), as with nuclear DNA, can be methylated by
machinery existing inside of the mitochondria [10-12]
and can mediate the control of mitochondrial gene ex-
pression [13]. Platelets lack a nucleus, and therefore, the
mitochondrial genome is the only genetic material in
these cells. Therefore, the epigenetic regulation of mito-
chondrial genes in platelets is critical to understanding
their implication in the development of CVD.
The mitochondria contain their own DNA molecules,
which are copies of a genome of approximately 17 kb in
circular form. The mitochondrial genome contains 37
genes, 13 of which are protein encoding while 24 encode
tRNAs and rRNAs. There are several aspects of the mito-
chondrial genome that distinguish it from the nuclear
genome. Firstly, the mitochondrial genome lacks histone
complexes and retrotransposons (such as LINE-1 and
Alu) [11]. Secondly, there are many copies of nuclearentral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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cytoplasmic mtDNA that has been incorporated into the
nuclear genome [14]. Thirdly, since the level of mtDNA
methylation is far less than that of nuclear DNA, the exist-
ence and function of mtDNA methylation has been de-
bated. However, there is growing evidence that mtDNA
methylation has been overlooked. Vanyushin BF et al. first
reported DNA methylation and DNA methyltransferase
(DNMT) activity in the mitochondria in 1971 [15]. Shock
et al. reported mitochondrial DNMT1 activity, mtDNA
methylation, and control of gene expression through this
pathway [16]. Byun et al. demonstrated a relationship be-
tween mtDNA methylation and environmental air pollu-
tion exposure - an established CVD risk factor - in healthy
humans [10]. Indeed, mitochondrial DNA methylation
has been proposed as a next-generation biomarker and
diagnostic tool [17]. As every cell type contains differing
numbers of mitochondria and different levels of their ac-
tivity, it is expected that mtDNA epigenetic patterns will
differ by tissue and cell type. Therefore, studying mito-
chondrial epigenetic patterns by single cell type is critical
to understand the effects of mtDNA methylation on
disease.
DNA methylation markers in the nuclear genome of
unfractionated peripheral blood lymphocytes (PBL) asso-
ciated with CVD risk have produced inconsistent results
[18-21] and have been particularly challenging to de-
velop. The possible reason for this difficulty is that PBLs
are a mixture of multiple leukocyte subtypes [22], and
therefore the observed changes in molecular markers in
at-risk individuals, which may differ in each of the cellular
subtypes, may simply reflect differences in the proportions
of circulating cellular subtypes [23]. Furthermore, each
leukocyte subtype has a variable risk-predictive relation-
ship with CVD [24]. Therefore, investigating platelet mito-
chondria provides a unique opportunity to solve the
biological riddle that arises with the use of a mixed popu-
lation of blood cells (PBLs/buffy coat). In addition to this,
studying a key blood cell type for CVD development
may provide greater insight into developing biomarkers
for CVD risk. Platelet mitochondria can be obtained
non-invasively and can be easily isolated from both
fresh and frozen plasma samples, thus they provide an
easy-to-handle biospecimen for clinical and preventive
applications. However, the efficacy of using mtDNA as
a biomarker has been controversial [17,25,26], mainly
due to the sensitivity and detection limitation associ-
ated with low levels of mtDNA methylation. Therefore,
it is critical to apply a sensitive technique to measure
mtDNA methylation levels, such as by bisulfite pyrose-
quencing [10], in order to understand the effect of this
epigenetic phenomenon in disease.
In this study, we measured and analyzed platelet mito-
chondrial DNA methylation levels of genes associatedwith ATP synthesis: three of four protein-encoding cyto-
chrome c oxidase genes associated with the electron
transport chain complex (MT-CO1, MT-CO2, and MT-
CO3); ATP synthase (MT-ATP6 and MT-APT8); and
NADH dehydrogenase (MT-ND5). Additionally, we ana-
lyzed the tRNA leucine 1 gene (MT-TL1) that is known
to have clinical significance [27-29] in CVD patients in
comparison to healthy individuals. We utilized bisulfite
pyrosequencing, which is a sensitive and well-established
DNA methylation detection method. We observed that
individuals with CVD showed higher methylation levels
than healthy individuals in several mitochondrial genes
in platelets.
Results
Characteristics of healthy individuals and CVD patients
We collected samples from 17 healthy individuals and 10
patients with CVD for the study. Due to failed pyrose-
quencing data points (see ‘Methods’ section), the number
of healthy individuals and CVD patients that are com-
pared for each gene differ slightly. Fifty-three percent of
the healthy individuals are males (9/17) in comparison to
30% of CVD patients (3/10). The mean ages of the healthy
individuals and CVD patients were 43.8 and 62.4 years,
respectively. Our study contained a mix of races. Among
the healthy individuals, 35% were Caucasian, 24% His-
panic, and 41% African-American. Among the CVD
patients, 40% were Caucasian, 20% Hispanic, 30% African-
American, and 10% Asian. The mean BMI was 30.4 for
healthy individuals and 27.5 for the CVD patients. All ten
CVD patients had hypertension, and the group also in-
cluded two patients with atherosclerosis, one patient with
atrial fibrillation, and three patients who were clinically di-
agnosed with CVD (Table 1). Patients were selected upon
the basis of diagnosis with hypertension and/or athero-
sclerosis, as these are the most common causes of CVD.
Platelet mtDNA methylation in healthy individuals and
CVD patients
We measured platelet mtDNA methylation in healthy
individuals and patients with CVD by bisulfite PCR
combined with pyrosequencing. Mean MT-CO1 DNA
methylation was 4.45% (min = 0 and max = 18.04, SD:
7.27) in healthy individuals and 22.97% (min = 16.87,
max = 28.49, SD: 3.17) in CVD patients. The difference
in mean mtDNA methylation levels between healthy in-
dividuals and CVD patients was 18.53% (P value
<0.0001, 95% CI: 13.25 to 24.20, by Mann–Whitney U
test) (Figure 1a). Mean MT-CO2 DNA methylation was
1.22% (min = 0 and max = 4.50, SD: 1.14) in healthy indi-
viduals and 4.55% (min = 1.23 and max = 6.11, SD: 1.52)
in individuals with CVD. The difference in mean
mtDNA methylation levels between healthy and CVD
individuals was 3.33% (P value = 0.0001, 95% CI: 2.13 to
Table 1 Details of the plasma samples from healthy individuals and CVD patients
Sample ID Gender Age Race BMI Diagnosis Medications
23 Male 46 Caucasian 25 - -
24 Male 71 Hispanic 24 - -
25 Male 54 Caucasian 34 - -
27 Male 50 African-American 30 - -
28 Male 38 African-American 34 - -
29 Male 23 African-American 23 - -
30 Male 22 Hispanic 24 - -
31 Male 59 Caucasian 28 - -
32 Male 52 African-American 32 - -
33 Female 52 Caucasian 34 - -
34 Female 59 Caucasian 31 - -
35 Female 44 Hispanic 26 - -
36 Female 41 Hispanic 30 - -
37 Female 19 African-American 54 - -
38 Female 26 African-American 27 - -
39 Female 48 Caucasian 32 - -
41 Female 41 African-American 28 - -
08 Male 62 Asian 25 Hypertension, high cholesterol, benign
prostatic hyperplasia
Flomax, Hyzaar, Zocor, Urocit, Vitamin D
09 Male 66 African-American 25 Hypertension, hypertensive cardiovascular
disease (HCVD)
Naprosyn, Flomax, Lisinopril, Toprol XL,
Norvasc, ASA, Lipitor, Aciphex
16 Male 64 Caucasian 26 Coronary artery disease, hypertension,
lung cancer
ASA, Carvediolol, Dexamethasone, Lovaza
1gram, Ramipril, Vytorin
10 Female 54 Hispanic 31 Atherosclerosis, hypertension Synthroid, tenoretic
11 Female 83 Caucasian 24 Atrial fibrillation, hypertension Coumadin 5 mg, Cardura
12 Female 44 Hispanic 26 Atherosclerosis, hypertension, chest pain Aspirin, Atenolol, Diovan HCT
13 Female 65 Caucasian 36 Hypertension, lung cancer, secondary
mal neoplasms
Keppra, Lisinopril Hydrochlorothyazide,
Metoprolol tartrate, Pravachol, Sucralfate,
Tarceva, Tarceva, Xanax
14 Female 55 African-American 31 Hypertension, end stage of kidney disease Cozaar, Renvella, Lasetalol
15 Female 59 Caucasian 27 Hypertension, high cholesterol, type 1
diabetes
Actonel, Advair, Benicar, Novolin, Caltrate,
Spiriva, Synthroid, Tocor
17 Female 72 African-American 26 Hypertension, heart disease, osteoarthritis,
type 2 diabetes
Endocet, Lantus, Ferrous Fumerate, Colace,
Aspirin, Simvastatin, Amlodipine, Hydralazine,
Lisinopril, Januvia
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0.58% (min = 0 and max = 1.24, SD: 0.39) in healthy indi-
viduals and 1.50% (min = 1.03 and max = 2.21, SD: 0.39)
in individuals with CVD. The difference in mean
mtDNA methylation levels between healthy and CVD
individuals was 0.92% (P value <0.0001, 95% CI: 0.56 to
1.30) (Figure 1c). Mean MT-TL1 DNA methylation levels
were 2.57% (min = 2.15 and max = 3.00, SD: 0.31) in
healthy individuals and 4.24% (min = 2.80 and max = 5.55,
SD: 0.82) in individuals with CVD. The difference in mean
mtDNA methylation levels between healthy and CVD indi-
viduals was 1.67% (P value = 0.0001, 95% CI: 1.00 to 2.25)
(Figure 1d). We did not observe significant differences inmtDNA methylation for MT-ATP6, MT-ATP8, or MT-ND5
(Figure 1e,f,g). We examined the association between
mtDNA methylation at each site and the age, BMI, race,
and gender of individuals, but none of these factors showed
a significant association (Additional file 1).
The predictive probability of platelet mtDNA methylation
as a CVD biomarker
To determine the predictive probability of platelet mtDNA
methylation as a CVD biomarker, we performed receiver
operating characteristic (ROC) curve analysis. Areas under
ROC curves (AUROCs) were estimated and compared by
chi-square test. The AUROC was 0.99 for MT-CO1 gene,
Figure 1 Distribution of percentage mtDNA methylation in healthy individuals and CVD patients. Distribution of percentage mtDNA methylation
in healthy individuals and CVD patients for (a) MT-CO1, (b) MT-CO2, (c) MT-CO3, (d) MT-TL1, (e) MT-ATP6, (f) MT-ATP8, and (g) MT-ND5 are shown.
The values from all individuals are displayed, with lines corresponding to the mean and 95% confidence interval
values. ****P < 0.0001;***P = 0.0001.
Baccarelli and Byun Clinical Epigenetics  (2015) 7:44 Page 4 of 90.94 for MT-CO2, 0.96 for MT-CO3, and 0.97 for MT-TL1.
The sensitivity and specificity were 100% and 90% for MT-
CO1 gene, 100% and 70% for MT-CO2, 100% and 70% for
MT-CO3, and 100% and 78% forMT-TL1 (Figure 2).
Purity determination of extracted mtDNA
In order to examine the extent of nuclear DNA contam-
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formed PCR amplification of a gene located in the mito-
chondrial genome (MT-CO1), two single-copy genes
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and a repetitive element (LINE-1) for which multiple
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converted DNA, as it was for the performance of pyro-
sequencing. We observed amplification of mtDNA
(MT-CO1) in both bisulfite-treated platelet mtDNA and
leukocyte DNA. However, we did not observe PCR ampli-
fication of the nuclear DNA-encoded CDH1, CDKN2A, or
LINE-1 in the extracted platelet mtDNA, demonstrating
absence of nuclear DNA in these samples. A representa-
tive gel is shown in Figure 3.Technical replicates and quantitative validation of
pyrosequencing assays
We performed technical replicates to assess the preci-
sion of mtDNA methylation determination, as well as to
confirm the observed small but significant differences in
mtDNA methylation for three selected assays: MT-CO1,
MT-CO2, and MT-CO3. The Spearman rank correlation
coefficient between technical replicates for the MT-CO1
assay (methylation range: 0.00% to 32.30%) was 0.97 (P
value <0.0001, 95% CI: 0.92 to 0.99) (Figure 4a). For the
MT-CO2 assay (methylation range: 0.00% to 6.31%), the
correlation was 0.93 (P value <0.0001, 95% CI: 0.82 to
0.97) (Figure 4b), and for MT-CO3 (methylation range:
0.00% to 2.25%), it was 0.76 (P value <0.0001, 95% CI:
0.51 to 0.89) (Figure 4c). In order to quantitatively valid-
ate our newly designed mtDNA pyrosequencing assays,
we used universal whole-genome unmethylated and
methylated DNA to serve as 0% and 100% methylation
controls, respectively. The measured methylation values
from amplification of these cell line-based controls was
compared to 0% and 100% methylated control oligonu-
cleotides, generated by synthesis of sequences with the
presence of a T or C nucleotide at the interrogated CpG
sites to represent 0% and 100% methylated DNA, re-
spectively. The MT-CO1 assay reported 2.2% methylation
in the cell line-extracted unmethylated control and 97.3%
in the methylated control (Figure 4d), the MT-CO2 assay
reported 2.3% methylation in the unmethylated control
and 91.8% in the methylated control (Figure 4e), and theMT-CO1 CDKN2A LINE-1 Mark
Extracted mtDNA  (BS treated)
(bp)
150
200
CDH1
Figure 3 A representative gel following PCR amplification of mitochondria
and LINE-1 in extracted mtDNA (lanes 1 to 4) and control DNA from huma
(lanes 6 to 9) were visualized on a 2% agarose gel. The fifth lane contains aMT-CO3 assay reported 0.4% in the unmethylated control
and 88.3% in the methylated control (Figure 4f).
Discussion
In this study, we hypothesized that DNA methylation in
platelet mitochondria is a potential contributor to CVD
development through modulation of platelet activity. We
examined platelet mtDNA methylation among healthy
individuals and CVD patients, and we observed signifi-
cantly higher mtDNA methylation of four genes in CVD
patients. The predictive probability analysis demon-
strates the potential utility in using platelet mtDNA
methylation levels as a CVD biomarker. The role of
mtDNA methylation in platelet function has yet to be
fully elucidated, but our data is the first to characterize
platelet mtDNA methylation as being implicated in
CVD.
Due to tissue-differential and cell type-differential
methylation patterns, using a mixture of multiple cell
types, as routinely found in human tissues, has long
been a critical hurdle in clinical studies [22,23]. Periph-
eral blood DNA - which is no easier to isolate than
platelet DNA - is derived from diverse types of leuko-
cytes. Similarly, vascular tissues, such as heart tissues
and blood vessels, are comprised of multiple cell types.
The main cell types found in heart tissues include endo-
thelial cells, epicardium cells, smooth muscle cells, car-
diomyocytes, and fibroblasts [30], while several others,
such as macrophages or white and red blood cells can
infiltrate the tissues. As CVD patients exhibit changes in
the counts and proportions of individual leukocyte sub-
types, as well as in the numbers of different cell types in
the heart and blood vessels, differences in DNA methyla-
tion observed in these composite tissue types that are
associated with CVD (and other diseases) have been sug-
gested to result solely from differences in cell type com-
position rather than from bona fide epigenetic changes.
Even in the presence of bona fide DNA methylation
changes independent of cell type compositions, analysis
of DNA isolated from whole tissue will inherentlyer
human adult normal peripheral 
blood leukocyte DNA (BS treated)
MT-CO1 CDKN2A LINE-1CDH1
l and nuclear DNA sequences. Amplification of MT-CO1, CDH1, CDKN2A,
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they cannot be traced to one or more of the specific cell
types within the tissue. Our study has the unique advan-
tage of being based on platelets, which is the only cell
type in the human body that can be readily isolated
without labor-intensive and costly procedures.
The mitochondrial genome is known to retain a very
low level of DNA methylation, and we observed low
levels of platelet mtDNA methylation in healthy individ-
uals, with higher mtDNA methylation in those with
CVD. The observed changes were relatively small in
magnitude, except for MT-CO1, yet distinct between
healthy and CVD individuals. What we observed in MT-
CO1 is an astounding difference (18.53%) in platelet
mtDNA methylation from CVD patients. Previous stud-
ies have reported no difference in nuclear DNA methyla-
tion in blood samples collected after ischemic heart
disease and/or stroke diagnosis compared with baseline
[19], while Movassagh et al. reported comparatively
small 2% to 5% differences in nuclear DNA methylation
in left ventricular tissue from four cardiomyopathy pa-
tients [31]. Taken together, these findings demonstrate
the utility of studying mtDNA methylation in platelets.
Furthermore, platelet mtDNA methylation patterns
showed little variation between individuals, which isperhaps the product of the study of a single cell type,
but nonetheless were markedly different by CVD status.
Compared to measured mtDNA methylation patterns
using DNA from buffy coats [10], methylation levels
were more homogenous in purified platelets. Further
work is required to establish whether the magnitude of
the observed changes in mtDNA methylation is suffi-
cient to alter transcription of mitochondrially encoded
genes or affect protein activity.
Platelets are involved in blood clot formation, and ab-
normal clotting is implicated in heart attacks, stroke,
and other CVD risks. Platelet dysfunction is also related
to activation and hyperaggregation, which are further
CVD risk factors [32]. The mitochondria play a critical
role in maintaining the normal function of the heart,
and therefore mitochondrial dysfunction is related to the
pathogenesis and development of various types of heart
disease [33]. We observed a significant increase in
mtDNA methylation of all three MT-CO subunits in
platelets from CVD patients. COX is a component of
the respiratory electron transport chain, with subunits 1
to 3 (MT-CO1, MT-CO2, and MT-CO3) forming the
functional core of complex IV. Genetic mutations in
COX genes are related to fatal metabolic disorders [34]
which predominantly affect tissues with high energy
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activity is related to sepsis mortality [35] that commonly
occurs with cardiac dysfunction. Dysfunctional COX
complexes are therefore known to be the most severe
among the many classified mitochondrial diseases [34].
However, further work is required regarding platelet
COX activity and quantity with regard to CVD.
Overweight and obese individuals have a high risk of
developing CVD [36]. We did not observe an association
between BMI and platelet mtDNA methylation in this
study. However, higher mtDNA methylation levels, simi-
lar to those in CVD cases, were observed in three
healthy individuals for MT-CO1 (BMI: 26, 28, and 34,
which correspond to being overweight and obese) and
one individual for MT-CO2 (BMI: 28, overweight)
(Figure 1). It has not been possible to obtain follow-up
data regarding whether these apparently healthy individ-
uals developed CVD after the samples were taken.
Whether platelet mtDNA can be a marker of CVD predis-
position among obese and overweight individuals is there-
fore not yet clear.
We obtained platelet pellets by centrifugation and
DNase I treatment to remove nuclear DNA on account
of the possibility of contamination of the samples with
NUMTs [37]. We did not observe any nuclear DNA in
our samples of extracted platelet mtDNA, which could
potentially have arisen from cell-free nuclear DNA or
from other blood cells. However, while nuclear DNA
could not be amplified by PCR in the extracted mtDNA,
we cannot exclude the possibility that a minor portion
of nuclear DNA contamination could still exist in our
extracted mtDNA. Therefore, caution is still required
with the application of other techniques for the study of
the mitochondrial genome, such as whole-genome se-
quencing or bisulfite sequencing.
We have chosen to use bisulfite pyrosequencing to
measure locus-specific mtDNA methylation. As exten-
sively proven, and also through our own experience, py-
rosequencing is the most reliable, sensitive, and robust
technique for studying DNA methylation. Therefore, we
opted to use this method instead of other available high-
throughput and genome-wide techniques, such as
whole-genome bisulfite mtDNA sequencing,
There are several limitations to our study. We ob-
tained plasma samples from donors, but the sample size
is relatively small in comparison to other clinical studies.
Nonetheless, we demonstrated both the feasibility of this
approach and report definitive results in the data. Most
importantly, this method is innovative and could prove
to be beneficial to other relevant studies. As our study is
a proof of principle, it can pave the way for larger-scale
studies concerning the function of platelet mtDNA
methylation in CVD development. While the CVD pa-
tients that we studied have multiple diagnoses, it iscommon to observe comorbidity of CVD with other dis-
ease types, and therefore it was inevitable to include in-
dividuals with complex diagnoses.
Our study is also limited by the possibility of contam-
ination with cell-free mitochondria in the platelet pellets
that were isolated. Cell-free mitochondria are highly un-
likely to be pelleted with platelets on account of the cen-
trifugation speed that was used (1,400 × g), as low-speed
centrifugation separates platelets from the smaller and
lighter particles, such as exosomes, microparticles, and
cell-free mitochondria that are pelleted at over 12,000 ×
g [38]. Nonetheless, the possibility of trace quantities of
cell-free mitochondria in the pellet cannot be excluded.
We therefore sought to optimize our method to obtain
platelet-enriched mtDNA by using DNase I treatment to
remove cell-free mtDNA, in addition to the use of low-
speed centrifugation to separate platelets from cell-free
mitochondria. We examined the centrifuged platelets
with transmission electron microscopy and confirmed
that majority of cells, if not all, were platelets (data now
shown due to a discrepancy of donor samples used for
the study). It has been reported that some of the cell-
free mitochondria present in plasma originate from
platelets themselves [39], and so trace contamination
with platelet-derived mitochondria and microparticles
that contain mtDNA should not affect measured methy-
lation levels, on account of the cells of origin being the
same. A further limitation of this study is that pyrose-
quencing analyses failed in some of the samples due to
an insufficient yield of mtDNA. We have purposely not
applied a method using platelet-rich plasma in order for
our findings to have greater significance through more
direct implications for studies with blood samples col-
lected by commonly used methods, such as those taken
in clinical routine blood drawing. However, it is indeed
possible to increase mtDNA yield and thereby increase
the range of techniques and approaches that can be uti-
lized when platelet-rich plasma is available.
Conclusions
Our study is the first to characterize the possible role of
platelet mitochondrial DNA methylation in relation to
CVD risk. Focusing on a single, pure cell population that
is critical to CVD etiology provides ease of interpretation
for DNA methylation patterns in relation to disease. As
platelets can be inexpensively isolated from stored
plasma, our study demonstrates a novel approach that
can be applied to many existing studies and which may
yield risk and diagnostic biomarkers for CVD.
Methods
Human plasma
We purchased 17 fresh frozen human plasma samples
from healthy individuals and 10 from individuals with
Baccarelli and Byun Clinical Epigenetics  (2015) 7:44 Page 8 of 9CVD (BioreclamationIVT, Baltimore, MD, USA). Infor-
mation about gender, ethnicity, age, diagnosis, and treat-
ment were available from the vendor (Table 1).
Extraction and bisulfite DNA conversion of mtDNA in
platelets
We centrifuged 400 μl of plasma samples at 1,400 × g for
15 min at room temperature to obtain platelet pellets.
To minimize contamination with nuclear DNA [37,40],
we added 3 μl of DNase I (Roche Holding AG, BASEL,
Switzerland, 10 U/μl), 3 μl incubation buffer (10×,
400 mM Tris–HCl, 100 mM NaCl, 60 mM MgCl2,
10 mM CaCl2; pH 7.9), and 3 μl water and incubated the
samples for 3 h at 37°C. After incubation, we followed
the protocol provided with the EZ DNA Methylation-
Direct™ Kit (Zymo Research Corp., Orange, CA, USA)
for extraction and sequential bisulfite-conversion of
mtDNA. Briefly, we treated the samples with Proteinase
K for 1 h at 50°C and centrifuged the samples at
10,000 × g to remove cell debris, with the supernatant
retained. The standard bisulfite conversion protocol pro-
vided by the kit manufacturers was followed, with elu-
tion of mtDNA in 10 μl of elution buffer.
Quantitative validation of pyrosequencing assay
We purchased universal methylated and unmethylated
DNA samples (Zymo Research Corp., Orange, CA, USA)
as 0% and 100% methylation controls. We used control ol-
igonucleotides for 100% DNA methylation (PSQ-C
oligo: 5′-TTGCGATACGACGGGAACAAACGTTG-3′)
and 0% DNA methylation (PSQ-T oligo: 5′-TTGCGATAC
AACGGGAACAAACGTTG-3′). The sequencing primer
for the control oligonucleotide is: 5′-AACGTTTGTTCCC
GT-3′. The PSQ-C oligonucleotide (or PSQ-T oligo-
nucleotide) and sequencing oligonucleotide were mixed
in annealing buffer. Pyrosequencing was performed
with a sequencing entry of C/TGTAT [41].
PCR and pyrosequencing
We designed nine assays to interrogate mtDNA methy-
lation based upon the GeneBank: J01415.2 (L-strand)
mitochondrial genome sequence using the Meth Primer
program [42]. The PCR and pyrosequencing primers are
provided in the Additional file 1. We measured three
CpGs sites for the MT-ATP6 assay and two CpGs for all
the other assays. We used 1 μl of bisulfite-treated
mtDNA for PCR reactions with 10 μl GoTaq Green
Master mix (Promega, Madison, WI, USA) and 10 μl of
PCR products for pyrosequencing using the PSQ Q96
MD pyrosequencing system (QIAGEN, Valencia, CA,
USA), as previously described. Briefly, 10 μl of PCR
products for each sequencing reaction were immobilized
on to streptavidin-coated beads (Streptavidin Sepharose
HP, GE Healthcare Biosciences, Pittsburgh, PA, USA) inbinding buffer (10 mM Tris–HCl, 2 M NaCl, 1 mM
EDTA, 0.1% Rweeb 20; pH 7.6) for 10 min. The biotin-
labeled template was purified using the pyrosequencing
vacuum prep tool (QIAGEN, Valencia, CA, USA) and
incubated with 10 pmol/reaction sequencing primer in
annealing buffer (20 mM Tris-acetate, 2 mM MgAc2;
pH 7.6). The DNA strands were denatured at 80°C for
2 min and reannealed at room temperature for 10 min.
Sequencing was performed according to manufacturer’s
instructions. The allele frequencies (% cytosine or % thy-
midine) were calculated from the peak heights, as ana-
lyzed by the allele quantification module in the PSQ 96
MD software (QIAGEN, Valencia, CA, USA). Percentage
methylation was determined by the ratio of cytosine-to-
thymidine conversion (methylation = % cytosine/(% cyto-
sine + % thymidine)). We have excluded results from
failed samples according to pyrosequencing built-in
quality controls.Statistical analysis
We performed non-parametric Mann–Whitney tests to
analyze the differences in mtDNA methylation between
healthy and CVD patients. To analyze technical du-
plications of pyrosequencing performance, we computed
Spearman’s rank correlation (r) as the data was not nor-
mally distributed. ROC curves were generated for each
mtDNA assay. Maximum mtDNA methylation levels
from healthy individuals for each marker were used as
cutoffs to determine the sensitivity, specificity, PPV, and
NPV. All graphs and statistical analysis were made using
the Prism software (GraphPad software, La Jolla, CA,
USA).Additional file
Additional file 1: Supplementary information 1, 2, and 3.
Supplementary information 1. Primer sequence and information.
Supplementary information 2. Platelet mtDNA methylation level with
age, BMI, and race. Supplementary information 3. Scatter plots of mtDNA
methylation from healthy individuals and CVD patients by age, BMI, and race.
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